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Abstract The aim of our study was to evaluate the ef- 
fects of intra-articular methotrexate (MTX) in patients 
with rheumatoid arthritis (RA) and psoriatic arthritis 
(PsA). Twenty-three consecutive patients, 10 with RA 
and 13 with PsA, with prevalent or unique arthritic 
involvement of one knee, were treated with intra-artic- 
ular injections of MTX 10 mg every 7 days for 8 weeks. 
Before the beginning of the treatment and after 9 and 
17 weeks, the patients underwent a clinical evaluation 
measuring maximal knee flexion angle, visual analog 
scale (VAS) and erythrocyte sedimentation rate (ESR). 
On the same days, an ultrasonographic examination of 
the involved knee was performed by two independent 
experienced operators. Synovial thickness in the supra- 
patellar bursa and the presence of joint effusion and 
Baker's cyst were assessed. An increase of the mean 
value of maximal knee flexion angle and a reduction of 
the mean values of ESR and VAS between TO, T9 and 
T17 were demonstrated. Ultrasonographic evaluation 
showed significant reduction of synovial thickness and 
joint effusion. No differences were detected for the 
presence of Baker's cyst. We may conclude that repeated 
intra-articular injections of MTX resulted in a decrease 
of local as well as systemic inflammatory signs. As far as 
we know, this is the first study that explores the effects of 
intra-articular MTX in RA and PsA both clinically and 
by ultrasonography. 
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Introdu~kion 
Intra-articular therapy is an often-used procedure in the 
treatment of mono-oligoarthritis, especially because it 
has the advantage of conveying the drug directly to the 
inflamed joint area, thus avoiding major systemic side 
effects. This kind of therapeutic approach requires 
specialised knowledge of anatomy and physiology of the 
musculoskeletal system as well as understanding of the 
pathology of rheumatic disorders. When properly indi- 
cated and performed, it carries minimal risk for the 
patient. Many different compounds may be injected; 
among them, corticosteroids are the most commonly 
used [1-4]. 
The modern treatment of inflammatory arthritides 
includes the early administration of disease-modifying 
antirheumatic drugs (DMARDs), which are considered 
to be effective in inhibiting the progression of joint 
damage. Methotrexate (MTX) is one of the most fre- 
quently used, since it is has been proved to influence the 
outcome of these diseases by reducing the incidence Of 
erosions. MTX acts by inhibiting d!hydrofolate r duc- 
tase, an essential enzyme for the biosynthesis of purinic, 
thymidylic and inosinic acids [5, 6]. Therapeutic effects 
are also thought o be due to the inhibition of methyla- 
tion reactions and the promotion of adenosine release [7, 
8] with final inhibition of toxic oxygen metabolite release, 
lymphocyte proliferation and production of tumour 
necrosis factor alpha (TNF-a), interleukin (IL)-6 and IL- 
8. MTX is also able to induce suppressor lymphocyte 
phenotype and function and to increase IL-10 production 
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[9-12]. MTX is usually administered weekly, with oral or 
parenteral low doses of 7.5-15 mg/week. Intra-articular 
administration has been reported, with possibly favour- 
able results [13-15] and rare negative side effects [16]. The 
local use of the compound is supported by the aim of 
achieving maximal anti-inflammatory and immunosup- 
pressive ffects on the synovial membrane [17, 18]. 
The present study was undertaken to evaluate the 
effects of intra-articular MTX in patients with knee joint 
synovitis, due to rheumatoid arthritis (RA) or psoriatic 
arthritis (PsA). Patients' serial assessment was based on 
the evaluation of clinical and laboratory parameters and 
on an ultrasonographic examination of the affected 
knee. Ultrasonography (US) was chosen as the imaging 
modality of reference, since it has been successfully ap- 
plied, in recent years, to the examination of joint alter- 
ations in many rheumatic disorders. In particular, US is 
currently considered a reliable imaging technique for the 
detection of joint effusion and synovial proliferation [19, 
20], which represent two of the main consequences of
synovitis [21, 22]. Moreover, due to the frequent com- 
munication between the gastrocnemiosemimembranous 
bursa and knee joint cavity, Baker's cysts can be fre- 
quently detected by US in the popliteal fossa when 
effusion is present. 
As far as we know, this is the first study that evaluates 
the effects of intra-articular MTX in RA and PsA by 
US. 
Methods 
Patients 
Twenty-three consecutive patients, 10 with RA and 13 
with PsA, with prevalent or unique arthritic involvement 
of one knee, who attended the outpatient Rheumatology 
Unit of the "La Sapienza" University, Policlinico Um- 
berto I of Rome, Italy, were recruited for the study. The 
PsA and RA patients atisfied the validated classification 
criteria for the correspondent disease [23, 24]. 
On the basis of the potential organ toxicity of MTX, 
patients with hepatic or pulmonary pathology were ex- 
cluded from the study. Subjects with signs of any other 
rheumatic disease were also excluded. Knee involvement 
was confirmed by clinical evaluation. 
All patients were under stable treatment with meth- 
ylprednisolone 4 mg/day and diclofenac 100 mg/day for 
2 months prior to the beginning of the study and carried 
on with this medication till the last follow-up. No other 
drug was added, no other intra-articular injection was 
performed and no topical application was used. 
The involved knee was injected with 10 mg sodium 
salt MTX once a week for 8 weeks. The drug was diluted 
in a 3 ml saline solution. From the 9th week, MTX was 
administered orally at a dose of 7.5 mg/week. The pa- 
tients were evaluated, both clinically and by US, before 
the beginning of the treatment (TO) and after 9 (T9) and 
17 (T 17) weeks. 
Clinical evaluation 
Maximal knee flexion angle was measured using a 
goniometer, the visual analog scale (VAS) was calcu- 
lated using a 10-cm horizontal scale with ten possible 
scores and a venous blood sample was taken to deter- 
mine erythrocyte sedimentation rate (ESR) values. 
Sonography 
US of the inflamed knee was performed with a 7.5-MHz 
linear probe (HP, Image Point HX System) by two dif- 
ferent operators experienced in musculoskeletal US and 
blinded to the patient's diagnosis as well as clinical and 
laboratory data. The exams were carried out separately. 
The suprapatellar bursa was scanned for the measure- 
ment of synovial thickness and the detection of effusion, 
while the posterior calf was explored for the presence of 
Baker's cyst. 
Synovial thickness was measured with the patient 
supine and the knee in neutral position as previously 
described [19, 25]. Measurements were done on the 
posterior wall of the synovial membrane, as it is better 
defined than the anterior wall, 2 cm above the superior 
pole of the patella, both in the transverse and longitu- 
dinal scans. The mean values of each couple of results 
were calculated. Measurements were repeated twice by 
both operators. According to previous studies [19], 
thickness of the synovial membrane was considered 
abnormal when higher than 3 ram. Joint effusion, sec- 
ondary to synovitis, was diagnosed when hypoanechoic 
fluid collection was shown within the articular space [19, 
25]. Finally, the presence of Baker's cyst was ascertained 
when fluid distension of the gastrocnemiosemimembra- 
nous bursa was demonstrated. 
Statistical analysis 
Student's t-test, the general inear model (GLM) re- 
peated measures procedure and McNemar's test were 
chosen to compare results. Findings were expressed by 
average and standard eviation parameters. Values of 
p < 0.05 were considered to be statistically significant. 
Results 
The ten RA subjects had polyarthritis with prevalent 
involvement of one knee. The group was formed by 
eight women and two men, with a mean age of 
35.5 years (range: 24-45) and a mean disease duration of 
6.3 years (range: 3-11). Among the 13 PsA patients, 5
had monoarthritis nvolving one knee (1 woman and 4 
men, mean age: 32.4 years, range: 25-39, mean disease 
duration: 1.9 years, range: 1-3) and 8 had oligoarthritis 
with prevalent involvement of one knee (4 women and 4 
men, mean age: 31.5 years, range: 20-42, mean disease 
duration: 1.1 years, range: 1-3). Clinical and US find- 
ings are reported in Table 1. 
Considering the total number of patients, maximal 
knee flexion angle (mean value) increased significantly 
between TO (57.6 °) and T9 (69.4 °, p < 0.000), between T9 
and T17 (73.3 °, p<0.000)  and between TO and T17 
(p<0.000). Analysing the single diseases, significant 
differences were found in RA between TO and T9 
(p<0.02), T9 and T17 (p<0.000) and TO and T17 
(p < 0.002); in PsA, differences were significant between 
TO and T9 (p<0.000), T9 and T17 (p<0.003) and TO 
and T17 (p < 0.000). 
A significant reduction was demonstrated in the mean 
values of the VAS between TO (RA: 6.60, PsA: 6.41, 
total: 6.59) and T9 (RA: 4.31, PsA: 3.58, total: 3.89), 
between T9 and T17 (RA: 3.96, PsA: 3.23, total: 3.55) 
and between TO and T17 (p < 0.000) both in the single 
RA and PsA cohorts than in the group taken as a whole• 
In the whole cohort of patients the mean values of 
ESR appeared significantly reduced between TO 
(44.4 mm/h) and T9 (38.3 mm/h, p < 0.000), between T9 
and T17 (35.7 mm/h, p < 0.000) and between TO and T17 
(p<0.000). Analysing the single diseases, significant 
differences were found in RA between TO and T9 
(p<0.015), T9 and T17 (p<0.008) and TO and T17 
(19 < 0.001); in PsA, differences were significant between 
TO and T9 (p < 0.000), T9 and T17 (p < 0.003) and TO 
and T17 (19 < 0.000). 
The US examinations did not show a significant in- 
traobserver (intraclass correlation coefficient 0.82-0.93, 
p<0.0001) and interobserver (intraclass correlation 
coefficient 0.85, p < 0.0001) variability. 
A significant reduction of the mean thickness of 
the synovial membrane (Fig. 1) was found in both 
groups of RA and PsA patients, as well as in the 
whole cohort examined, between TO (RA: 5.72 mm, PsA: 
5.34mm, total: 5.50 ram) and T9 (RA: 5.05 mm, 
PsA: 4.69 mm, total: 4.83 mm), between T9 and T17 
(RA: 4.80 mm, PsA: 4.54 mm, total: 4.65 mm) and 
between TO and T17 with a p < 0.000. 
When examining the whole cohort of patients, sig- 
nificant differences were present in the incidence of joint 
effusion between TO (12 cases) and T9 (four joints, 
p<0.027) and between TO and T17 (three knees, 
p < 0.008). No significant difference was found within the 
single groups of RA and PsA patients, due to the low 
number of positive cases• 
Since Baker's cyst was found only in a limited num- 
ber of patients (TO: five cases, T9: two knees, T17: one 
joint), statistical analysis did not show significant dif- 
ferences during the follow-up. 
I~eur ,~n 
One of the main characteristics of RA and PsA is the 
presence of synovitis, which provokes the appearance of 
joint effusion and synovial proliferation, due to synovial 
hyperplasia and hypertrophic changes [20--22, 26]. The 
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entity of these alterations is strictly correlated to the 
activity and severity of the inflammatory process [20, 25, 
26]. The US analysis reliably detects both abnormalities 
and it is thus considered an accurate imaging method for 
the study of synovitis [19, 27-29]. Previous studies 
demonstrated that magnetic resonance analysis of a 
single sagittal slice and US measurements of synovial 
thickness in the suprapatellar bursa are reliable and 
accurate methods for the quantification of the severity of 
the inflammatory process in RA and in Sj6gren's yn- 
drome patients [19, 30, 31]. 
The use of colour and power Doppler has recently 
made the application of US in the evaluation of syno- 
vitis possible. Unfortunately, due to the lack of stan- 
dardization of different parameters, these techniques are 
still considered very user dependent [20] and often 
present difficulties in the quantification of alterations. 
The effects of intra-articular MTX have been previ- 
ously evaluated with controversy and inconstantly 
favourable results [16-18, 32-37]. As far as we know, 
this is the first study that investigates the effects of intra- 
articular MTX in RA and PsA both clinically and by 
ultrasound. 
Our findings uggest a local anti-inflammatory action 
of MTX, demonstrated by the reduction of the signs of 
synovitis (joint effusion and synovial thickness) in the 
serial US examinations of the treated knees in both 
RA and PsA patients. The positive effect of the drug 
is also supported by the increase of the mean maximal 
knee flexion angle, the decrease of the mean VAS 
values and the significant reduction of the mean ESR 
values. 
In conclusion, the present report confirms the 
important role played by US in the depiction of knee 
Fig. 1 Sonography of the knee 
in a patient with PsA. The 
thickness of the synovial 
membrane (I) is measured in 
the suprapatellar bursa 
(transverse scan),  Thickness 
of the synovial membrane 
before the beginning of the 
intra-articular MTX treatment. 
b Thickness of the synovial 
membrane 17 weeks after the 
beginning of the intra-articular 
MTX treatment 
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joint synovitis in chronic arthritides. The use of intra- 
articular MTX appeared to be effective in reducing local 
inflammatory activity. Further studies are warranted to 
confirm this result and to demonstrate he possible sys- 
temic effects of this local treatment. 
The non-invasiveness, low cost, reproducibility and 
quickness of US represent relevant advantages in respect 
to other more expensive and scarcely available imaging 
methods. These characteristics render ultrasound an 
important and manageable tool in the assessment of 
synovitis in arthritic patients as well as in the evaluation 
of the effects of treatment. 
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